Gavi et al. (1) investigated the association between visceral adipose tissue (VAT) mass by computed tomography and circulating retinol-binding protein-4 (RBP4) concentrations in nondiabetic subjects. They could not find a correlation between VAT and serum RBP4 concentrations, while VAT was inversely correlated with serum adiponectin concentrations in their subjects. The study by Gavi et al. did not support specific association between circulating RBP4 concentrations and abdominal obesity, which we (2) and Graham et al. (3) observed in previous studies. However, it is in accordance with the observation by Takashima et al. (4) that serum RBP4 concentrations were not correlated with waist-to-hip ratio in 473 nondiabetic subjects (mean ± SD age 64.8 ± 11.1 years). Different study populations as well as different measure of abdominal obesity might contribute to this inconsistency between circulating RBP4 concentrations and abdominal obesity. Although Gavi et al. directly measured visceral fat mass, they studied only 16 nondiabetic individuals with narrow range of BMI (24.6 ± 0.8 kg/m2), whose clinical and metabolic characteristics are not provided. Thus, it is somewhat difficult to compare their observation with our results. In a recent report, Janke et al. (5) found that RBP4 mRNA was downregulated in subcutaneous tissue of obese women, and circulating RBP4 concentrations were similar in normal weight, overweight, and obese postmenopausal women (n = 74). These data suggest that the differences exist between different adipose tissue depots in the regulation of RBP4 expression and secretion. Interestingly, it was shown (6) that elevation in circulating RBP4 concentrations was strongly correlated with visceral fat mass, and RBP4 mRNA expression was significantly higher in visceral fat compared with subcutaneous fat, independent of sex and type 2 diabetes (n = 196). Nevertheless, as recognized by Gavi et al. (1), it is necessary to reevaluate the correlation between circulating RBP4 levels and visceral fat mass with a larger population.

1.
Gavi S, Qurashi S, Melendez MM, Mynarcik DC, McNurlan MA, Gelato MC: Plasma retinol-binding protein-4 concentrations are elevated in human subjects with impaired glucose tolerance and type 2 diabetes (Letter).
Diabetes Care
30
:
e7
,
2007
. DOI:
2.
Cho YM, Youn BS, Lee H, Lee N, Min SS, Kwak SH, Lee HK, Park KS: Plasma retinol-binding protein-4 concentrations are elevated in human subjects with impaired glucose tolerance and type 2 diabetes.
Diabetes Care
29
:
2457
–2461,
2006
3.
Graham TE, Yang Q, Bluher M, Hammarstedt A, Ciaraldi TP, Henry RR, Wason CJ, Oberbach A, Jansson PA, Smith U, Kahn BB: Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects.
N Engl J Med
354
:
2552
–2563,
2006
4.
Takashima N, Tomoike H, Iwai N: Retinol-binding protein 4 and insulin resistance.
N Engl J Med
355
:
1392
,
2006
5.
Janke J, Engeli S, Boschmann M, Adams F, Bohnke J, Luft FC, Sharma AM, Jordan J: Retinol-binding protein 4 in human obesity.
Diabetes
55
:
2805
–2810,
2006
6.
Klöting N, Berndt J, Fasshauer M, Schön MR, Stumvoll M, Blüher M: Retinol binding protein 4 (RBP4) serum concentrations and fat depot specific mRNA expression in humans (Abstract).
Diabetologie und Stoffwechsel
1
:
A319
,
2006
[article in German]